<DOC>
	<DOCNO>NCT00787202</DOCNO>
	<brief_summary>The hypothesis study least one dose CP 690 550 superior placebo ( inactive drug ) induce remission patient moderate severe ulcerative colitis .</brief_summary>
	<brief_title>A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis .</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients must least 18 year age screening Males female patient clinical diagnosis ulcerative colitis ≥3 month prior entry study . Male female patient active currently moderate severe ulcerative colitis define Mayo score ≥6 Patients endoscopic subscore ≥2 Mayo score determine within 7 day baseline . Diagnosis Crohn 's disease diagnosis indeterminate colitis Treatment naive subject previous exposure treatment ulcerative colitis Patients currently receive immunosuppressant , antiTNFα therapy interferon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>treatment ulcerative colitis ; CP 690 550</keyword>
</DOC>